Analyst: 'New CEO, Larger Sales Team and Greater SUI Focus Should Help Medical Device Growth'

Research Report
  ()
Cowen analyst Dr. Joshua Jennings highlighted this medical device firm’s Q1/18 developments and financial results. read more >

Biotech Announces Encouraging HIV Vaccine Results

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics. read more >

Shovelnose Delivers Gold to Westhaven

Contributed Opinion
  ()
Bob Moriarty of 321 Gold profiles a company that holds a large land position in the "most unexplored gold belt in British Columbia." read more >
Management Q&A: View from the Top

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way

Managment Q&A: View from the Top
  ()
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. read more >

Biotech's Launch of Pain Product Shows Encouraging Early Metrics

Research Report
  ()
Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset. read more >

Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company

  ()
The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment. read more >

Concurrent Milestones for Biotech Set to Occur 'on the Horizon'

Research Report
  ()
Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news. read more >

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease

  ()
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. read more >

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

  ()
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. read more >

Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate. read more >
Expert Investing Ideas

"DRRX reported its Q1/18, mostly in line with expectations."

–Francois Brisebois, Laidlaw & Company


"IMV announced it has applied to list on NASDAQ."

–André Uddin, Mackie Research Capital


"VIVE's cash as of Q4/17 was $20.7M."

–Jeff Cohen, Ladenburg Thalmann


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Biotech Round-Up: M&As, Financings and Immuno-Oncology

Contributed Opinion
  ()
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. read more >

Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data. read more >

Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal

  ()
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. read more >

Biotech Announces Positive Topline Data in Tourette Syndrome

Research Report
  ()
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. read more >